Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases

Stopped early · Phase 1

Conditions studied: Metastatic Cancer

In brief

RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.

Key facts

Study ID

NCT00028652

Run by

University of Wisconsin, Madison

Starts

2002-01-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.